AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc US ((AZNCF)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc ((GB:AZN)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca, in collaboration with Parexel International, is set to commence a clinical study titled A Randomised, Double-blind, Multi-centre, Placebo-controlled, Crossover Study to Assess the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler on Cardiac and Lung Function in Participants With Chronic Obstructive Pulmonary Disease and Hyperinflation. The study aims to evaluate the effects of the BGF MDI compared to a placebo on heart and lung function in COPD patients, highlighting its potential significance in improving treatment outcomes for this condition.
The intervention being tested is the Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI), which is designed to enhance cardiac and pulmonary function in COPD patients. The study will also use a placebo MDI for comparison purposes.
This Phase IV study is interventional, employing a randomized, double-blind, placebo-controlled crossover design. Participants will be randomly assigned to receive either the BGF MDI followed by a placebo or vice versa, ensuring unbiased results. The primary purpose is treatment-focused, aiming to establish the efficacy of the BGF MDI.
The study is scheduled to start on November 14, 2025, with the primary completion and estimated completion dates yet to be determined. The last update was submitted on August 4, 2025, indicating the study’s preparatory phase is underway.
The announcement of this study could positively influence AstraZeneca’s stock performance and investor sentiment, given the potential for BGF MDI to become a significant treatment option for COPD. This development may also impact competitors focusing on respiratory treatments, as successful outcomes could shift market dynamics.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.